JPH10245391A5 - - Google Patents

Info

Publication number
JPH10245391A5
JPH10245391A5 JP1997047963A JP4796397A JPH10245391A5 JP H10245391 A5 JPH10245391 A5 JP H10245391A5 JP 1997047963 A JP1997047963 A JP 1997047963A JP 4796397 A JP4796397 A JP 4796397A JP H10245391 A5 JPH10245391 A5 JP H10245391A5
Authority
JP
Japan
Prior art keywords
group
acceptable salt
active ingredient
physiologically acceptable
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1997047963A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10245391A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP9047963A priority Critical patent/JPH10245391A/ja
Priority claimed from JP9047963A external-priority patent/JPH10245391A/ja
Publication of JPH10245391A publication Critical patent/JPH10245391A/ja
Publication of JPH10245391A5 publication Critical patent/JPH10245391A5/ja
Pending legal-status Critical Current

Links

JP9047963A 1997-03-03 1997-03-03 7−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤 Pending JPH10245391A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9047963A JPH10245391A (ja) 1997-03-03 1997-03-03 7−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9047963A JPH10245391A (ja) 1997-03-03 1997-03-03 7−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤

Publications (2)

Publication Number Publication Date
JPH10245391A JPH10245391A (ja) 1998-09-14
JPH10245391A5 true JPH10245391A5 (cg-RX-API-DMAC7.html) 2004-12-02

Family

ID=12790005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9047963A Pending JPH10245391A (ja) 1997-03-03 1997-03-03 7−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤

Country Status (1)

Country Link
JP (1) JPH10245391A (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
EP1273578B1 (en) 2001-06-28 2005-02-23 Dainippon Ink And Chemicals, Inc. Benzopyran derivatives and antiallergic agent containing the same
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
EP2291189B1 (en) 2008-05-22 2014-10-01 AstraZeneca AB Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
US9545610B2 (en) 2013-03-04 2017-01-17 Nova Chemicals (International) S.A. Complex comprising oxidative dehydrogenation unit
CN104945455B (zh) * 2014-03-28 2019-01-01 中国医学科学院药物研究所 香豆素苷类化合物、其制法和药物组合物与用途
CN104861020B (zh) * 2015-06-14 2017-05-17 海南医学院 一个苯丙素苷类化合物、其提取方法及其应用
JOP20210009A1 (ar) 2018-07-19 2021-01-12 Astrazeneca Ab طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
JP2023536009A (ja) 2020-07-27 2023-08-23 アストラゼネカ・アクチエボラーグ ダパグリフロジンによる慢性腎疾患の処置方法
WO2022208172A1 (en) 2021-04-01 2022-10-06 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
IL329013A (en) 2023-12-15 2026-08-01 Astrazeneca Ireland Ltd SGLT2 inhibitors and baxadrostat for the treatment of chronic kidney disease and hypertension

Similar Documents

Publication Publication Date Title
CA2136999A1 (en) Peripheral vasodilating agent containing piperidine derivative as active ingredient
CA2309350A1 (en) Purine derivatives and medicaments comprising the same as active ingredient
BG103277A (en) Application of sibutramine analogues for the prevention of diabetes development
PL315636A1 (en) Cosmetic or pharmaceutic compositions containing magnipherine or its derivatives
CA2015475A1 (en) Treating agent for osteoarthritis
CA2402609A1 (en) Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
CA2341568A1 (en) Stabilized pharmaceutical composition in lyophilized form
IL112515A (en) Pharmaceutical composition containing N,N-dimethyl-1-¬1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine for use in the treatment of non-insulin dependent diabetes mellitus
CA2102591A1 (en) Hypoglycemic Agent
CA2257016A1 (en) Imidazolidin-4-one derivatives useful as anticancer agents
KR930703303A (ko) 1, 4-벤조티아제핀 유도체
CA2299308A1 (en) Cyclohexenone long-chain alcohol and medicament containing same
JP2002519425A5 (cg-RX-API-DMAC7.html)
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
CA2190993A1 (en) Protective agent for organ or tissue
RU2003134629A (ru) Соединения цефема
CA2365359A1 (en) Medicaments containing a sulfopyranosylglycerol derivative
JP2000169325A5 (cg-RX-API-DMAC7.html)
CA2373484A1 (en) Use of 1,4-benzothiazepine derivatives as drugs for overcoming resistance to anticancer drugs
CA2196215A1 (en) 1,4-dihydropyridine compound and pharmaceutical composition containing the same
CA2317673A1 (en) Novel allylthiopyridazine derivatives and process for preparing the same
EP1103253A3 (en) Aqueous film coating agent and oral solid preparation
IT1254280B (it) Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
KR950008502A (ko) 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제